cell lines murine t lymphoma el4 cells atcc  (ATCC)

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy

doi: 10.1007/s00262-026-04302-5

Figure Lengend Snippet: TCRfullvax design and characterization. ( A ) TCRfullvax design representing order in which each TCR chain was included. ( B ) Schematic representation of immunization schedule for TCRfullvax immunogenicity characterization. ( C ) Mean IFNγ spots generated against TCRα, TCRβ and TCRγ chains by the TCRfullvax. ( D ) IFNγ spots generated against each peptide pool derived from the TCRα chain. ( E ) IFNγ spots generated against each peptide pool derived from the TCRβ chain. ( F ) IFNγ spots generated against each peptide pool derived from the TCRγ chain. ( G ) Schematic of tumor challenge testing efficacy of TCRfullvax with EL4 cells in vivo. ( H ) Mean EL4 tumor sizes in mice treated with TCRfullvax or empty vector control pVax. ( I ) Survival of EL4 tumor bearing mice demonstrating statistically significant improvement in survival of mice treated with TCRfullvax

Article Snippet: The EL4 cell line was purchased from ATCC.

Techniques: Immunopeptidomics, Generated, Derivative Assay, In Vivo, Plasmid Preparation, Control

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy

doi: 10.1007/s00262-026-04302-5

Figure Lengend Snippet: TCRfullvax-treated tumors have greater CD8+ T cell infiltration. ( A ) CD8+ T cell infiltration in tumors of mice immunized with either pVax or TCRfullvax. ( B ) %PD1 expression on CD8+ T cells in tumors of mice immunized with either pVax or TCRfullvax. ( C ) %KLRG1 expression on CD8+ T cells in tumors of mice immunized with either pVax or TCRfullvax. ( D ) PD1 MFI on CD8+ T cells in tumors of mice immunized with either pVax or TCRfullvax. ( E ) KLRG1 MFI on CD8+ T cells in tumors of mice immunized with either pVax or TCRfullvax. ( F ) %TCRβ+ TCRVβ12+ (TCR expressing EL4 cells) in tumors of mice immunized with either pVax or TCRfullvax. ( G ) Flow cytometry plots showing TCRβ+ TCRVβ12+ double positive cells in tumors of mice immunized with either pVax or TCRfullvax

Article Snippet: The EL4 cell line was purchased from ATCC.

Techniques: Expressing, Flow Cytometry

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy

doi: 10.1007/s00262-026-04302-5

Figure Lengend Snippet: EL4neovax controls EL4 tumors in mice. ( A ) Schematic of tumor challenge testing efficacy of EL4neovax with EL4 cells in vivo. ( B ) Mean EL4 tumor sizes in mice treated with EL4neovax or empty vector control pVax. ( C ) Tumor size of each individual mouse treated with either EL4neovax or pVax. ( D ) Survival of EL4 tumor bearing mice demonstrating improvement in survival of mice treated with EL4neovax

Article Snippet: The EL4 cell line was purchased from ATCC.

Techniques: In Vivo, Plasmid Preparation, Control

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy

doi: 10.1007/s00262-026-04302-5

Figure Lengend Snippet: Synergistic effect of TCRfullvax and EL4neovax. ( A ) Schematic of tumor challenge testing synergy of TCRfullvax and EL4neovax for controlling EL4 cells in vivo. ( B ) Mean EL4 tumor sizes in mice treated with TCRfullvax, EL4neovax, both vaccines co-delivered or empty vector control pVax. ( C ) Tumor size of each individual mouse treated with either TCRfullvax, EL4neovax, both vaccines co-delivered or pVax. ( D ) Survival of EL4 tumor bearing mice demonstrating improved survival of mice treated with combination therapy compared to either vaccine alone

Article Snippet: The EL4 cell line was purchased from ATCC.

Techniques: In Vivo, Vaccines, Plasmid Preparation, Control

Journal: Nature Communications

Article Title: Aiolos restricts the generation of antigen-inexperienced, virtual memory CD8 + T cells in mice

doi: 10.1038/s41467-025-67540-8

Figure Lengend Snippet: Analysis of Eomes expression in CD8 + T cells isolated from the spleens of uninfected WT and Ikzf3 -/- mice. a Representative flow contour plots depicting expression of Eomes in WT and Ikzf3 -/- CD8 + T cells; and b respective bar graphs showing percent (%) of Eomes + and numbers of Eomes-expressing CD8 + T cells (# counts, normalized to 6 × 10 5 events). c Representative histogram overlay for Eomes expression and associated data showing differences in median fluorescence intensity (MFI) fold change relative to WT control. For ( a – c ), data shown for 4 independent experiments, n = 14/group, mean ± SEM, two-sided, unpaired Student’s t-test, ****p ≤ 0.0001. d Representative flow plots and e associated bar graphs showing percent (%) of CD122 + and numbers of CD122-expressing CD8 + T cells (#: counts, normalized to 6 × 10 5 events), Data shown for 3 independent experiments, n = 11/group, mean ± SEM, two-sided, unpaired Student’s t-test, ****p ≤ 0.0001. f Analysis of publicly available Aiolos Chromatin Immunoprecipitation (ChIP)-Seq data (GSM5106065) and STAT5b ChIP-Seq data (GSM7887512) showing enrichment of Aiolos and STAT5b at the Eomes promoter region. Sequencing tracks were viewed using Integrative Genomics Viewer. The gene region cloned into a reporter vector for Eomes promoter activity is indicated. g , h EL4 T cells were transfected with an Eomes promoter-reporter construct in conjunction with vectors for Aiolos, Aiolos DNA binding mutant (Aiolos DBM) , constitutively active STAT5b (STAT5b CA ), or empty vector control. As a control for transfection efficiency, cells were concurrently transfected with SV40- Renilla , and luciferase activity was used as a readout for promoter activity. Luciferase promoter-reporter values were normalized to SV40- Renilla control and presented as relative to the empty vector. Immunoblot analysis of the indicated proteins confirming the overexpression of respective vectors. β-actin was used as a loading control. Data are representative of 4 independent experiments, n = 4/condition, mean ± SEM, one-way ANOVA with Tukey’s multiple comparisons test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001. Source data are provided as a file.

Article Snippet: The EL4 murine T cell lymphoma line (TIB-39) for transfection studies and YAC-1 cells (TIB-160) for cytotoxicity were acquired from the American Type Culture Collection (ATCC) and maintained in complete RPMI (RPMI media [catalog # 61870-036, Thermo Fisher Scientific] containing 10% FBS [catalog # 26140-079, Life Technologies] and 1% penicillin/streptomycin [catalog # 15140-122, Life Technologies]).

Techniques: Expressing, Isolation, Fluorescence, Control, Chromatin Immunoprecipitation, ChIP-sequencing, Sequencing, Clone Assay, Plasmid Preparation, Activity Assay, Transfection, Construct, Binding Assay, Mutagenesis, Luciferase, Western Blot, Over Expression